Abstract | PURPOSE OF REVIEW: RECENT FINDINGS:
Tumor necrosis factor blockers have been shown to have rapid and persistent efficacy with limited additional toxicity up to 4 years with continuing therapy, but cessation of therapy results in relapse in most patients. Therapy is cost-effective. There are some differences between the different tumor necrosis factor blockers currently available. Other biologic therapies are not as promising. Algorithms have been developed to aid in early diagnosis. This may be relevant for future therapeutic strategies. SUMMARY:
|
Authors | Jane Zochling, Jürgen Braun |
Journal | Current opinion in rheumatology
(Curr Opin Rheumatol)
Vol. 17
Issue 4
Pg. 418-25
(Jul 2005)
ISSN: 1040-8711 [Print] United States |
PMID | 15956838
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antirheumatic Agents
- Immunologic Factors
- Tumor Necrosis Factor-alpha
|
Topics |
- Antirheumatic Agents
(therapeutic use)
- Early Diagnosis
- Humans
- Immunologic Factors
(therapeutic use)
- Rheumatology
(trends)
- Severity of Illness Index
- Spondylitis, Ankylosing
(physiopathology, therapy)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|